Background: In the era of precision medicine, Next-Generation Sequencing (NGS) has emerged as an important tool for identifying targetable mutations and tailoring treatment options. Yet the Middle East and North Africa (MENA) lags behind in adopting this technology. This study aims to demonstrate the transformative potential of molecular profiling in the region. Methods: This retrospective study reviewed cancer patients at the American University of Beirut Medical Centre, comparing outcomes between those who received NGS-based treatment adjustments (NBTAs) and those who did not. Results: The study enrolled 180 patients, including those with non-small-cell lung cancer (21.2%), sarcomas (20%), gastrointestinal malignancies (23.3%), breast cancer (10.6%), and other cancers (24.9%); 58.3% had stage 4 cancer at diagnosis. Before molecular profiling, 20.6% had stable disease, 21.7% showed partial response, and 57.8% had progressive disease. Most (96%) had received treatment, mainly systemic (90%), with chemotherapy (89%) being the most common. Forty patients (22.2%) underwent NGS-based treatment adjustments (NBTAs). Post-NGS, targeted therapies increased from 35% to 43% and immunotherapies from 14% to 18%. Mutations were detected in 98% of patients, with a median of four mutations per patient. NBTA patients had a median overall survival of 59 months, compared to 23 months for non-NBTA patients (p = 0.096), and significantly improved progression-free survival (5.32 vs. 3.28 months, p = 0.023). Conclusions: The use of large-scale molecular profiling to guide treatment adjustments promises advancements in patient care. Integrating NGS into clinical practice correlates with improved PFS, calling for a broader adoption of its use in the MENA region.

Background: Sarcomas are rare, aggressive malignancies with limited therapeutic options in advanced stages. This is the first real-world study in the MENA region evaluating the clinical utility of Next-Generation Sequencing (NGS) in guiding sarcoma treatment and improving outcomes. Methods: We retrospectively reviewed sarcoma patients who underwent NGS at a major referral center (2021–2024), comparing clinical and molecular outcomes between those who received NGS-based treatment adjustments (NBTA) and those who did not. Results: Seventy-eight patients were included (60% male; median age 44 years). Soft tissue sarcomas accounted for 70.5% of cases (n = 55), while bone sarcomas represented 29.5% (n = 23). Prior to NGS, 64.1% of patients had received a median of one line of systemic therapy. NGS was performed late in the disease course in 73% of cases. At least one mutation was detected in 87% (median 3 mutations). Targetable alterations were identified in 33% at the time of testing, rising to 42% with updated genomic knowledge and therapeutic advances. Overall, 20.5% received NBTA. Among non-NBTA patients, 67% had no actionable targets, 17% had no detectable mutations, and 16% were ineligible due to cost, limited access, or clinical deterioration. Tumor Mutational Burden was low in 79%, intermediate in 19%, and high in 2%, and all tumors were microsatellite stable. Patients receiving NBTA had a longer median Progression-Free Survival (9 vs. 2 months; p = 0.023). Median Overall Survival was longer in the NBTA group (74 vs. 48 months), though not statistically significant (p = 0.207). Genomic alterations were subtype-specific: EWSR1 rearrangements (Ewing and Desmoplastic small round cell tumors), CDK4 and MDM2 amplifications (Liposarcoma and Osteosarcoma), TP53 and RB1 mutations (Leiomyosarcoma), CDKN2A/B deletions (Undifferentiated Pleomorphic Sarcoma and Chondrosarcoma), and SS18 rearrangements (Synovial Sarcoma). Conclusions: Genomics-guided therapy in sarcoma is feasible and impactful. Expanding timely access to molecular profiling is essential for advancing precision oncology in the MENA region.

Immune checkpoint inhibitors (ICIs) have significantly improved outcomes across multiple malignancies but are associated with immune-related adverse events, including colitis. Although generally uncommon, ICI-induced colitis can lead to significant morbidity and treatment interruption, and data on its incidence and risk factors in the Middle East remain limited. We conducted a retrospective study of adult cancer patients treated with ICIs at a tertiary care center between December 2018 and March 2023. Clinical and treatment-related variables were collected, and univariable and multivariable logistic regression analyses were performed to identify predictors of colitis. Among 784 patients, 19 (2.4%) developed ICI-related colitis. Most cases were moderate to severe, and 57.9% required hospitalization, with a median length of stay of 7 days. All patients had advanced disease. Endoscopic evaluation, performed in 42.1% of patients, demonstrated heterogeneous disease distribution. ICI therapy was discontinued in 78.9% of patients and resumed in 36.8%. Corticosteroids were administered in 68.4% of patients, with a response rate of 92.3%; 1 patient required infliximab. One colitis-related death occurred. In univariable analysis, autoimmune disease, CTLA-4 inhibitor exposure, combination immunotherapy, and concurrent targeted therapy were significantly associated with colitis. In multivariable analysis, autoimmune disease ( OR =6.10, 95% CI: 1.55–24.08; P =0.010), combination immunotherapy ( OR =3.56, 95% CI: 1.09–11.63; P =0.035), and concurrent targeted therapy ( OR =3.88, 95% CI: 1.31–11.54; P =0.015) remained independent predictors. ICI-induced colitis is an uncommon but clinically meaningful toxicity, and recognizing patients at higher risk may help guide closer monitoring and improve clinical management.